Intravenous immunoglobulin (IVIg) is a purified plasma product that is used for many immune-deficient conditions and autoimmune conditions. Use of IVIg for treatment for Kawasaki disease (KD) is critical for control of inflammation. The American Heart Association (AHA) recommends a single infusion of 2 g/kg preferably given during the first 10 days of illness. In this review, we have discussed the possible mechanisms of action of IVIg in KD and its clinical usage in this condition.
Intravenous immunoglobulin (IVIg) is a purified product collected from the pooled blood of several thousands of the donors. Originally developed as replacement therapy for hypogammaglobulinemic and other immune-deficient patients, its indications have expanded over time to include many autoimmune and inflammatory conditions as well.
MECHANISM OF ACTION
IVIg is used to treat a wide variety of rheumatologic and other autoimmune disorders, despite an incomplete understanding of its mechanism of action. 1 Several different mechanisms have been proposed to explain the anti-inflammatory effect of IVIg. These include: increased clearance of autoantibodies through competitive binding of neonatel Fc receptors (FcRn); activation of inhibitory Fc receptor FccRIIB on macrophages; and blockade of adhesion molecules important for inflammatory cell trafficking to vascular endothelium. 2 It is also thought that IVIg preparations may contain antibodies capable of neutralizing cytokines, chemokines and activated complement proteins. It may be that select mechanisms have varying importance depending on the condition being treated. In one study, peripheral blood lymphocytes from KD patients demonstrated increased proliferative and decreased apoptotic responses when compared to cells from healthy controls. Treatment with IVIg resolved these differences, suggesting a pro-apoptotic effect. 3 This effect may be mediated by Fas, as IVIg preparations appear to contain anti-Fas antibodies. 4 IVIG may also influence the number and function of regulatory T cells (Tregs) which help control inflammation. Children with KD show lower Treg numbers in the acute phase of illness compared to healthy controls, and this normalizes after IVIg therapy. 5, 6 In another study, an expanded population of Treg cells recognizing the Fc portion of immunoglobulin was found in the peripheral blood of KD patients convalescing after IVIg therapy.
7 Interestingly, these Fc-specific Treg cells were not seen in patients with coronary artery abnormalities who were deemed IVIG non-responders, suggesting that modulation of Tregs may play a role in IVIg's mechanism of action in KD. also been reported. [8] [9] [10] IVIg has further been shown to inhibit T cell activation, tumor necrosis factor (TNF)-a production, and matrix metalloproteinase 9 (MMP9) activity that appear to mediate vascular damage in a mouse model of KD.
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The clinical response to IVIg in KD has yielded additional insights into its anti-inflammatory effects. Shrestha et al. found that specific polymorphisms of the inhibitory FccRIIB receptor corresponded with likelihood of response to IVIg, as might be expected based on previously proposed mechanisms of IVIg action. 12 The same group also evaluated polymorphisms of activating Fc receptors and found that the NA1 variant of FccRIIIB was associated with lack of response to IVIg; this receptor is expressed predominantly on neutrophils, which are important in the pathogenesis of coronary artery changes in KD.
13 IVIg non-response is also correlated with elevated serum levels of gamma glutamyl transferase (GGT); accordingly, gene expression profiling of a cohort of 130 KD patients was used to identify genes implicated in both IVIg non-response as well as GGT elevation.
14 High expression of ST6GALNAC3 was found to be strongly associated with IVIg resistance. ST6GAL-NAC3 encodes a sialyltransferase that adds a sialic acid residue to b-galactosidase, resulting in the ganglioside GD1a. GD1a, in turn, may bind siglec-9, a sialic acidbinding lectin on the cell surface of monocytes and neutrophils. As antibodies against siglec-9 in IVIg preparations have been described to induce neutrophil apoptosis, 15 the authors hypothesized that increased ST6GALNAC3 expression results in high GD1a levels that block the ability of IVIg to act through siglec-9. 15 Finally, there has been ongoing speculation that infectious etiologies may underlie KD pathogenesis. If so, IVIG may potentially neutralize microbial antigens, including superantigens. 16 
INITIAL DESCRIPTIONS OF IVIG IN KD
In 1981, IVIg was first used to treat a child with congenital agammaglobulinemia and secondary immune thrombocytopenic purpura (ITP). 17 The child's platelet count responded remarkably well to IVIg replacement therapy, and after this observation was made, high-dose IVIg was subsequently used to treat several more children with ITP.
17 Anti-platelet IgG and circulating immune complexes characterize the pathophysiology of ITP; the authors hypothesized that high doses of IVIG might saturate or overload the reticuloendothelial system through which platelets are cleared. Based on this report, in 1983, Furusho et al. first described the use of IVIg in 14 patients with KD. 18 They used a similar protocol of 400 mg/kg daily for 5 days. IVIg shortened the duration of illness and none of the treated patients developed coronary artery aneurysms. 18 The proposed rationale was that KD vasculitis may also be mediated by circulating immune complexes, for which high-dose IVIg might limit damage.
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Furusho and colleagues subsequently published a randomized controlled trial (RCT) of comparing aspirin (ASA) alone (30-50 mg/kg/day; 47 patients) to IVIg plus ASA (46 patients). At 30 days after onset of illness, 23% in the ASA alone group had persistent coronary artery abnormalities, in comparison to 2% of those who had received IVIg. 19 In North America, a multicenter RCT compared high-dose ASA (80-120 mg/kg/day; 84 patients) with IVIg plus ASA (IVIg 400 mg/kg/day for 4 days; 84 patients). Here again, there was conclusive evidence of efficacy, with the prevalence of coronary artery abnormalities at 2 and 7 weeks after treatment approximately three-to five-fold lower, respectively, among patients who received IVIg.
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REFINEMENT OF IVIG DOSING
Lower doses of IVIg were subsequently studied by multiple groups with variable success. 21 In one multicenter Japanese RCT of 160 patients, a 5-day protocol was trialed using three different doses: 50-100 mg/kg/day, 200 mg/kg/day and 400 mg/kg/day. Only the highest dose showed a beneficial effect on coronary artery outcomes. 22 Another Japanese study of 136 patients using 400 mg/kg/day for only 3 days also found benefit over ASA alone, although 23% of those who had received IVIg still had persistent fever. 23 With the goal of shortening the hospital stay for KD patients, a North American group compared a single infusion of 1 g/kg to 400 mg/kg/day for 4 days. 24 Although clinical recovery was faster among those who received the single infusion, coronary artery outcomes were not different in this small study of 47 patients. 24 In a larger North American multicenter RCT of 549 patients, Newburger et al. next compared the use of a single 2 g/kg dose of IVIg to the four-infusion protocol. 25 The children were evaluated at 2 and 7 weeks after treatment. Overall, those who received the single infusion did better, with less fever, shorter duration of fever, and lower frequency of coronary artery abnormalities, particularly at the 2-week mark. There was no difference in the rate of adverse events. 25 A later study similarly found that a single dose of 2 g/kg was more cost-effective than 400 mg/kg/day for 5 days.
A meta-analysis published in 1995 evaluating different IVIg dosing regimens concluded that doses > 1 g had better outcomes than lower-dose regimens. Among high-dose regimens, a single infusion fared better than multiple-dose protocols when coronary artery outcomes were measured at 30 days, but outcomes were similar at 60 days. 27 A later Cochrane review reached the same conclusions, and also noted that different preparations of IVIg did not yield different outcomes. 21 Accordingly, guidelines issued by the American Heart Association (AHA) in 2004, and reinforced in 2017, recommend a single infusion of 2 g/kg for initial management of KD at most institutions.
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TIMING OF THERAPY
The timing of IVIg therapy appears critical for achieving the best outcome. Furusho's initial RCT required treatment within 7 days of the onset of illness, while Newburger's 1986 trial required treatment within 10 days.
19,20 Rowley et al. reviewed their center's retrospective experience and noted that only three of 68 patients treated with IVIg developed coronary artery abnormalities. 30 Of these, one did not receive treatment until after the 10th day of illness. The authors suggest that treatment with IVIg should be within the first 10 days of illness.
Marisini et al. described a cohort of seven patients who received IVIg later, at a mean of 16 days after onset. 31 Coronary artery abnormalities were already present in all of the children, including giant aneurysms in two patients. Interestingly, all patients showed eventual normalization of their coronary arteries over the course of 2 years follow-up. A case-control study using a Japanese national database compared 75 patients treated with IVIg between days 11 and 20 of illness, with pair-matched controls treated between days 4 and 8. 32 Approximately half of the late IVIg group had coronary artery lesions at the time of therapy, and, of these, half normalized in the convalescent phase (> 1 month after onset). However, overall outcomes remained worse, with 27% of patients having coronary artery lesions in the convalescent phase as compared to 1% in the early IVIg group. 32 Among patients who did not have coronary artery lesions before IVIg therapy, the rate of developing lesions in the acute phase was similar regardless of timing of IVIg; however, in the convalescent phase, late IVIg patients still fared worse (5% vs. 1% with coronary artery lesions). 32 In contrast, using the same database, retrospective comparison of KD patients treated before the 5th day of illness to patients treated conventionally between days 5 and 9 demonstrated that early treatment was more likely to result in need for additional IVIg therapy (16% vs. 9%). Cardiac outcomes were not different. 33 Studies in other population groups have found similar results, 34, 35 although one study did find lower rates of coronary ectasia at 1 year in patients treated early. 36 Many experts believe that children who present with complete features before the 5th day of illness have more severe disease. Thus, treatment is not typically withheld until after the 5th day if patients are recognized to have KD earlier.
The AHA recommends treating with IVIg within 10 days of illness, and ideally within 7 days. If diagnosis is made after the 10th day, the AHA recommends treating if there is still fever or if aneurysms are present with laboratory evidence of active inflammation.
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IVIG RESISTANCE
Much work has been done to characterize the minority of patients who do not respond to initial therapy with IVIg. Risk factors associated with IVIg resistance include male sex, young age, high C-reactive protein, high neutrophil count and early presentation, among others. [37] [38] [39] [40] Several risk scores have been developed in an attempt to preemptively identify patients at risk. Although these scoring systems performed well in Japanese cohorts, they were less predictive of IVIg nonresponse in a North American cohort. 41 
ADVERSE EVENTS
Commonly reported side effects of the use of IVIg include headache, fever and myalgias. 42 Aseptic meningitis has been reported in 0-1% of patients. 43 Other rare side effects include anaphylaxis, nephrotoxicity and thromboembolic events. 42 IVIg-related hemolysis is also well-documented, although not usually clinically significant. The hemolysis is presumably mediated by anti-A and anti-B antibodies, although the titer of these antibodies within commercial preparations is tightly regulated. One case series reported a prevalence rate of 1.6%; nearly all of the cases had non-O blood group, had received high cumulative doses of IVIg, and had elevated inflammatory markers. 44 Examination of anti-A and anti-B IgG from the preparations used at that institution were found to be within acceptable limits.
The role of pre-existing inflammation in increasing risk for IVIg-related hemolysis is interesting. In a retrospective case review of IVIg-related hemolysis at a pediatric institution, all five identified patients had received IVIg for KD. 45 Another group reported that 16% of their KD patients treated over a 14-month interval developed IVIg-related hemolysis; all had required retreatment with IVIg, and hemolysis was observed after the second dose. 46 One hypothesis is that acute inflammation may upregulate Fc receptors on monocytes and macrophages, increasing their affinity for red blood cells opsonized by IgG. 47 In addition to receiving high doses of IVIg, KD patients may be more susceptible to IVIg-related hemolysis simply by nature of age. A review of case reports in the literature noted that pediatric cases showed a larger mean drop in hemoglobin as compared to the adult cases; the authors speculated that this may be due to the better ability of red blood cells from younger patients to bind immune complexes. 48 
CONCLUSION
IVIg is a critically important therapy in the treatment of KD although its anti-inflammatory effects remain incompletely understood. Recent investigations into IVIg responsiveness in KD have uncovered several new insights. Work remains ongoing to understand why some patients are resistant to treatment with IVIg, and to determine which additional treatments are optimal for these patients.
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